harpoon
therapeutics
abstract
epcam
program
accepted
oral
presentation
upcoming
sitc
annual
meeting
south
san
francisco
globe
newswire
harpoon
therapeutics
nasdaq
harp
immunotherapy
company
developing
novel
cell
engagers
announced
today
preclinical
data
treatment
solid
tumors
accepted
oral
presentation
society
immunotherapy
cancer
sitc
annual
meeting
virtual
meeting
takes
place
november
targets
tumor
antigen
epcam
based
harpoon
proprietary
cell
engager
prodrug
platform
designed
enable
effective
targeting
broadly
expressed
tumor
antigens
full
details
presentation
follows
abstract
title
cell
engager
improved
safety
profile
treatment
solid
tumors
presenter
jack
lin
session
bispecific
antibodies
cancer
immunotherapy
date
time
november
est
copy
presentation
available
company
website
https
shortly
event
harpoon
designed
platform
expand
universe
addressable
targets
indications
cell
engagers
ind
enabling
studies
underway
first
clinical
candidate
applies
prodrug
concept
create
therapeutic
cell
engager
remains
inactive
reaches
tumor
upon
entering
tumor
proteases
cleave
blocking
domain
thereby
enabling
engagement
cells
subsequently
kill
tumor
cells
activation
process
also
diminishes
resulting
cell
engager
active
molecules
leave
tumor
tissue
rapidly
eliminated
body
limiting
potential
side
effects
normal
tissues
harpoon
therapeutics
harpoon
therapeutics
immunotherapy
company
developing
novel
class
cell
engagers
harness
power
body
immune
system
treat
patients
suffering
cancer
diseases
cell
engagers
engineered
proteins
direct
patient
cells
kill
target
cells
express
specific
proteins
antigens
carried
target
cells
using
proprietary
cell
activating
construct
platform
harpoon
developing
pipeline
novel
tritacs
initially
focused
treatment
solid
tumors
hematologic
malignancies
targets
psma
phase
trial
metastatic
prostate
cancer
targets
mesothelin
phase
trial
cancers
expressing
mesothelin
including
ovarian
pancreatic
cancers
targets
bcma
phase
trial
relapsed
refractory
multiple
myeloma
targets
harpoon
plans
initiate
trial
second
half
additional
information
harpoon
therapeutics
please
visit
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
plan
anticipate
target
estimate
intend
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
harpoon
therapeutics
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
could
cause
harpoon
therapeutics
clinical
development
programs
future
results
performance
differ
significantly
expressed
implied
statements
statements
contained
press
release
include
limited
statements
progress
timing
scope
anticipated
results
clinical
trials
timing
presentation
data
association
data
potential
treatment
outcomes
development
advancement
product
candidates
timing
development
milestones
product
candidates
anticipated
potential
impacts
harpoon
therapeutics
business
ongoing
pandemic
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
observed
clinical
studies
clinical
trial
site
activation
enrollment
rates
lower
expected
unanticipated
greater
anticipated
impacts
delays
due
changes
expected
existing
competition
changes
regulatory
environment
uncertainties
timing
regulatory
approval
process
unexpected
litigation
disputes
factors
may
cause
harpoon
therapeutics
actual
results
differ
expressed
implied
statements
press
release
discussed
harpoon
therapeutics
filings
securities
exchange
commission
including
risk
factors
sections
contained
therein
except
required
law
harpoon
therapeutics
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
contacts
harpoon
therapeutics
georgia
erbez
chief
financial
officer
media
westwicke
icr
robert
uhl
managing
director
